Company: NCEL
Filing Date: 2025-03-10
Form Type: 425
Source: 0001213900-25-021979
Chunk: 4

Company: NewcelX Ltd.
Filing Date: 2025-03-10
Form: 425
Chunk 4
---
 track record of developing and commercializing
product candidates. For more information, please visit www.nlspharma.com.

About Kadimastem

Kadimastem is a clinical stage cell therapy company,
developing “off-the-shelf”, allogeneic, proprietary cell products based on its technology platform for the expansion and differentiation
of Human Embryonic Stem Cells (hESCs) into functional cells. AstroRx®, the company’s lead product, is an astrocyte cell therapy
in clinical development for the treatment for ALS and in pre-clinical studies for other neurodegenerative indications.

IsletRx is the company’s treatment for diabetes.
IsletRx is comprised of functional pancreatic islet cells producing and releasing insulin and glucagon, intended to treat and potentially
cure patients with insulin-dependent diabetes. Kadimastem was founded by Professor Michel Revel, Chief Scientific Officer of Kadimastem
and Professor Emeritus of Molecular Genetics at the Weizmann Institute of Science. Professor Revel received the Israel Prize for the invention
and development of Rebif®, a multiple sclerosis blockbuster drug sold worldwide. Kadimastem is traded on the Tel Aviv Stock Exchange
(TASE: KDST).

<div align='center'>3</div>

Social Media: LinkedIn,
X, Facebook, Instagram

Safe Harbor Statement

This press release contains expressed or implied
forward-looking statements pursuant to U.S. Federal securities laws. For example, NLS and Kadimastem are using forward-looking statements
when they discuss the expected closing, and the timing of the closing, of the transaction and the potential benefits of the transaction
to NLS and Kadimastem and their respective shareholders, including value creation for shareholders, as well as the expected strategic
position of the combined company following the Merger, if completed, and the plan to prepare and initiate a Phase IIa multi-site clinical
trial of AstroRx®, Kadimastem’s product candidate for Amyotrophic Lateral Sclerosis (ALS). These forward-looking statements
and their implications are based on the current expectations of the management of NLS and Kadimastem and are subject to a number of factors
and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The following
factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: risks related
to the companies’ ability to complete the Merger on the proposed terms and schedule, including risks and